Evolus Achieves Second Consecutive Quarter of Positive Adjusted EBITDA and Terminates $50M ATM Program

summarizeSummary

Evolus reported positive Adjusted EBITDA for Q1 2026, terminated a $50 million ATM program without selling shares, and reaffirmed its full-year guidance, signaling improved financial health and reduced dilution risk.

check_boxKey Events

• Achieves Positive Adjusted EBITDA

  Evolus reported $0.6 million in Adjusted EBITDA for the first quarter of 2026, marking the second consecutive quarter of profitability and a significant improvement from a $5.5 million loss in the prior year period.

• Terminates $50 Million ATM Program

  The company terminated its 'at-the-market' sales agreement, which had authorized the sale of up to $50.0 million in common stock. No shares were sold under this program prior to termination, removing a potential dilutive overhang.

• Reaffirms Full-Year 2026 Outlook

  Evolus reiterated its full-year 2026 net revenue guidance of $327 million to $337 million and continues to expect to achieve a low- to mid-single digit Adjusted EBITDA margin.

• Discloses Potential Tariff Impact

  The company noted a potential 15% U.S. tariff on patented pharmaceuticals from South Korea, which could affect its Jeuveau® product starting September 29, 2026, but stated it has flexibility to mitigate near-to-medium term impacts.

auto_awesomeAnalysis

Evolus's Q1 2026 results demonstrate a significant operational turnaround, achieving positive Adjusted EBITDA for the second consecutive quarter, which is a key milestone for the company's financial health. The termination of the $50 million 'at-the-market' program, under which no shares were sold, removes a substantial potential dilutive overhang (approximately 13.7% of current market cap), signaling improved capital position or reduced need for immediate external financing. While a new potential tariff on Jeuveau® from South Korea presents a future risk, the company's stated mitigation strategies temper immediate concerns. The reaffirmation of full-year guidance further reinforces management's confidence in continued growth and profitability.